Breast Cancer Clinical Trials

Showing 2581-2600 of 4,817 trials

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

NCT03630809

The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines. There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence. This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. Dendritic cells are immune cells that can tell the participant's immune system to fight infection. This study vaccine will be made from the participant's blood cells collected from a procedure called leukapheresis.

Breast CancerHER2-positive Breast CancerHER-2 Gene Amplification+4 more

H. Lee Moffitt Cancer Center and Research Institute16 participantsStarted Jan 2019

Tampa, Florida, United States

COMPLETEDPhase 2

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

NCT03628066

This study will look at the safety and effectiveness of the combination of palbociclib and letrozole and ovarian suppression for premenopausal patients who have ER-positive/HER2-negative breast cancer that has not yet been treated.

Breast Cancer

NSABP Foundation Inc24 participantsStarted Oct 2018

Fountain Valley, California, United States • Fountain Valley, California, United States • Laguna Hills, California, United States +12 more locations

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer

Related Searches

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Effectiveness of Mobile Messenger-initiated Reminder on Biannual Mammography Adherence in Breast Cancer Screening

Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

A Study of LY3023414 in Participants With Advanced Cancer

Promoting Earlier Detection of Breast Cancer in Rwanda: Scaleup in the National Health Care System

Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative Early Breast Cancer Patients

Genetic Predictors of Response to Acupuncture for Cancer-related Fatigue Among Breast Cancer Patients After Chemotherapy

A Trial of HRS-8080 Tablets in Metastatic or Local Advanced Breast Cancer of Adults

Phase II Study of Everolimus Beyond Progression

Vaccination With Autologous Breast Cancer Cells Engineered to Secrete Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Metastatic Breast Cancer Patients

Assessment of Feasibility and Acceptability of Personalized Breast Cancer Screening

Real Time Tissue Characterisation Using Mass Spectrometry REI-EXCISE iKnife Study

Implantation of CEST and CESL MRI Methods for Detection of Breast Tumors

Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

The Role of Interleukin-7 Serum Level as Biological Marker in Breast Cancer